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’INTRODUCTION
Tumor-associated cell cycle defects, manifesting in unscheduled
proliferation, and the associated genomic and chromosomal
instabilities are mediated by misregulation of cyclin-dependent
kinases (Cdks).
1 Because of the main role in the division cycle,
Cdks have been recognized as targets for anticancer therapy.
Many small-molecule organic compounds, which have been identi-
ﬁed as Cdk modulators, are currently in preclinical or clinical
development.
1 5However,noCdkinhibitorshavegainedmarketing
approval, despite 20 years of scientiﬁc investigation.
1
Several studies have shown synergism when Cdk inhibitors
were combined with organic (e.g., doxorubicin, paclitaxel)
2,6
and inorganic (e.g., cisplatin, carboplatin)cytotoxic drugs.
7 9
The reported eﬀects inspired the design of metal complexes
with biologically active ligands. The ﬁrst publications have
appeared recently and include Fe, Cu, and Pt complexes with
Cdk inhibitors derived from 6-benzylaminopurine,
10 13 metal-
basedindolo-[3,2-d]benzazepines(paullones;Ga,Cu,Ru,and
Os),
14 19 and indolo-[3,2-c]quinolines (Ru, Os).
20
Another class of compounds potentially suitable for targeted
metal-based chemotherapy is that of 3-(1H-benzimidazol-2-yl)-
1H-pyrazolo[3,4-b]pyridines. These have been documented re-
cently as potent Cdk1 inhibitors with antiproliferative activity in
HeLa (cervical carcinoma), HCT116 (colon carcinoma), and
A375 (melanoma) human cancer cell lines.
21 23 Comparison of
Cdk1 inhibitory activity with the inhibiting activity in four other
protein kinases (VEGF-R2, HER2, Aurora-A, and RET) revealed
selectivity for Cdk1. Structural modiﬁcations consisting of a
replacement of both bicyclic rings in 3-(1H-benzimidazol-2-yl)-
1H-pyrazolo[3,4-b]pyridines by monocycles while retaining the
imidazolyl pyrazole core have been proposed in order to obtain
inhibitors with improved pharmacokinetic and solubility pro-
perties.
24 26 The most promising were suggested to be 3-(1H-
benzimidazol-2-yl)-1H-pyrazolo[3,4-b]pyridines (see Chart 1).
The inspection of substitution patterns on the benzimidazole
moiety and structure activity relationships revealed that a meth-
oxymethyl group in position 7b (4b0) is favorable for Cdk1
inhibiting potency. The role of the pyrazole NH group is also of
note, since its methylation led to a signiﬁcant reduction of Cdk1
activity. The eﬀect of various heteroaryl groups in position 5a was
also remarkable for the development of more-eﬀective Cdk
inhibitors and antiproliferative agents.
Ourpreviousexperiencewithmetal-basedindolo-[3,2-d]benza-
zepinespromptedtheuseofthehalf-sandwichmetal-arenemoiety
as a suitable scaﬀo l dt ow h i c h3 - ( 1 H-benzimidazol-2-yl)-1H-
pyrazolo[3,4-b]pyridines may be attached. Organometallic com-
pounds [M(η
6-arene)(YZ)X]
n (where M = Ru, Os) exhibit
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ABSTRACT:Sixorganometalliccomplexesofthegeneralformula
[M
IICl(η
6-p-cymene)(L)]Cl,whereM=Ru(11a,12a,13a)orOs
(11b, 12b, 13b) and L = 3-(1H-benzimidazol-2-yl)-1H-pyrazolo-
[3,4-b]pyridines (L1 L3) have been synthesized. The latter are
known as potential cyclin-dependent kinase (Cdk) inhibitors.
All compounds have been comprehensively characterized by
elemental analysis, one- and two-dimensional NMR spectroscopy,
UV vis spectroscopy, ESI mass spectrometry, and X-ray crystal-
lography (11b and 12b). The multistep synthesis of 3-(1H-benzi-
midazol-2-yl)-1H-pyrazolo[3,4-b]pyridines (L1 L3), which was
reported by other researchers, has been modiﬁed by us essentially
(e.g., the synthesis of 5-bromo-1H-pyrazolo[3,4-b]pyridine-3-carboxylic acid (3) via 5-bromo-3-methyl-1H-pyrazolo[3,4-
b]pyridine (2); the synthesis of 1-methoxymethyl-2,3-diaminobenzene (5) by avoiding the use of unstable 2,3-diaminobenzyl
alcohol; and the activation of 1H-pyrazolo[3,4-b]pyridine-3-carboxylic acids (1, 3) through the use of an inexpensive coupling
reagent, N,N0-carbonyldiimidazole (CDI)). Stabilization of the 7b tautomer of methoxymethyl-substituted L3 by coordination to a
metal(II) center, as well as the NMR spectroscopic characterization of two tautomers 7b-L3 and 4b0-L3 in a metal-free state are
described. Structure activity relationships with regard to cytotoxicity and cell cycle eﬀects in human cancer cells, as well as Cdk
inhibitory activity, are also reported.11716 dx.doi.org/10.1021/ic201704u |Inorg. Chem. 2011, 50, 11715–11728
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promising anticancer activity and are the focus of attention for
several groups.
27 32 These compounds have shown activity toward
classic(DNA)andnonclassic(e.g.,Cdks)targetsinanticancer
chemotherapy.
Herein, we report (i) the modiﬁed synthetic approach to
3-(1H-benzimidazol-2-yl)-1H-pyrazolo[3,4-b]pyridines (recall
Chart 1: L1,X=H ,Y=H ;L2, X = Br; Y = H; L3, X = Br;
Y=C H 2OCH3); (ii) the synthesis and characterization of a new
family of organoruthenium(II) (11a, 12a, 13a) and osmium(II)
(11b, 12b, 13b) complexes of the general formula [MCl(η
6-p-
cymene)L]Cl,whereL =3-(1H-benzimidazol-2-yl)-1H-pyrazolo-
[3,4-b]pyridines (L1 L3) (Chart 1); (iii) stabilization of the 7b
tautomerofmethoxymethyl-substitutedL3bymetalcoordination
as well as (iv) NMR spectroscopic characterization of two
tautomers 7b-L3 and 4b0-L3 in a metal-free state; and (v) cell
cycle eﬀects, as well as the antiproliferative and Cdk inhibi-
tory activities of both metal-free ligands and organometallic
complexes.
’EXPERIMENTAL SECTION
Starting Materials. 3-Acetyl-2-chloropyridine and 3-methyl-1H-
pyrazolo[3,4-b]pyridinewerepreparedaccordingtoliteratureprotocols.
33 35
1H-Pyrazolo[3,4-b]pyridine-3-carboxylic acid (1) was obtained via the
oxidation of 3-methyl-1H-pyrazolo[3,4-b]pyridine by KMnO4 in the
presence of a base,
35 followed by acidification with 37% HCl. 2-Amino-
3-nitrobenzyl alcohol was obtained as reported in the literature.
36 1,
2-Diaminobenzeneanddrydimethylformamide(DMF)werepurchased
from Acros Organics. Solvents [toluene, ethanol (EtOH), tetrahydro-
furan (THF), diethyl ether (Et2O)] were dried using standard proce-
dures. [Ru
IICl(μ-Cl)(η
6-p-cymene)]2and [Os
IICl(μ-Cl)(η
6-p-cymene)]2
were synthesized as described previously.
37,38
Synthesis of Ligands. 5-Bromo-3-methyl-1H-pyrazolo[3,4-b]-
pyridine (2). 3-Methyl-1H-pyrazolo[3,4-b]pyridine (10.9 g, 0.08 mol)
and anhydrous sodium acetate (10.21 g, 0.13 mol) were suspended in
glacial acetic acid (42 mL). Bromine (20.42 g, 0.13 mol) was added,
and the resulting mixture was stirred at room temperature for 2 2.5 h
andthenat110 115Cfor2.5 3h.Afterward,water(300 350mL)
was added and the mixture was stirred at room temperature. The
formed light yellow precipitate was filtered off and dried in vacuo at
40 50 C. Yield: 17 g. The raw product was used without further
purification in the next step. Purification by column chromatography
afforded a white powder(SiO2,EtO Ac,R f = 0.79;12.5g,72.6% yield).
Mr (C7H6BrN3) = 212.05 g/mol. ESI-MS in MeOH (positive): m/z
213 [M+H]
+, 235 [M+Na]
+, 253 [M+K]
+;( n e g a t i v e ) :m/z 211
[M H]
 .
1H NMR (500.32 MHz, MeOH-d4): δ 8.55 (d, 1H, J =
2.16 Hz, CH), 8.43 (d, 1H, J =2 . 1 5H z ,C H), 2.56 (s, 3H, CH3) ppm.
1H NMR (500.32 MHz, DMSO-d6): δ 13.42 (brs, 1H, NH), 8.54 (d,
1H,J=2.19Hz,CH),8.53(d,1H,J=2.18Hz,CH),2.49(s,3H,CH3)
ppm. Colorless crystals of 230.5H2O suitable for X-ray diffraction
(XRD) study were grown in EtOAc (see Figure S1 in the Supporting
Information).
5-Bromo-1H-pyrazolo[3,4-b]pyridine-3-carboxylic acid (3). To so-
diumhydroxide(9.54g,0.24mol)inwater(150mL)wasaddedtheraw
product 2(7.1 g, 0.03 mol). After a dropwise addition of KMnO4(16.98 g,
0.11mol)inwater(300mL)at100Cover2h,thereactionmixturewas
further heated for 1 h. MnO2 was filtered off from the hot reaction
mixture and washed with hot water. The filtrates were combined, the
water was evaporated to ca. 400 mL, and the yellow solution was
acidified to pH ∼2, using concentrated HCl. The yellow precipitate was
filtered off and dried in vacuo at 60 C. Yield: 2.28 g. The crude
hydrochlorideof3wasusedwithoutfurtherpurificationinthenextstep.
Mr(C7H4BrN3O2) = 242.03 g/mol. ESI-MS in MeOH (positive): m/z
243 [M+H]
+, 265 [M+Na]
+, 287 [M+2Na H]
+; (negative): m/z 241
[M H]
 .
1H NMR (500.32 MHz, MeOH-d4): δ 8.69 (d, 1H, J = 2.22
Hz, CH), 8.68 (d, 1H, J = 2.22 Hz, CH) ppm.
1H NMR (500.32 MHz,
DMSO-d6): δ 14.65 (s, 1H, NH), 13.45 (brs, 1H, NH), 8.72 (d, 1H, J =
2.23 Hz, CH), 8.58 (d, 1H, J = 2.25 Hz, CH) ppm.
1-Methoxymethyl-2-amino-3-nitrobenzene(4).NaH(1.75g,0.07mol)
was suspended in dry THF (200 mL). A solution of 2-amino-3-nitrobenzyl
alcohol(5.23g,0.03mol)indryTHF(100mL)wasaddeddropwiseat0C
and the mixture was stirred at the same temperature for 15 min. After a
dropwise additionofMeI (11.5 g, 0.08 mol), stirringwascontinued at room
Chart 1. Compounds Reported in This Work with Atom Numbering Schemes for NMR Signal Assignment
a
aUnderlined compounds have been characterized by X-ray diﬀraction (XRD).11717 dx.doi.org/10.1021/ic201704u |Inorg. Chem. 2011, 50, 11715–11728
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temperature for 3 h. A saturated aqueous solution of NaHCO3
(300 mL) and MeOH (300 mL) then were added. The mixture was
filtered,andthewhiteprecipitatewaswashedwithEtOAc.Thefiltrates
were combined, and organic solvents were evaporated under reduced
pressure. The remaining aqueous solution was extracted with EtOAc
(2   300 mL). The organic phase was dried over Na2SO4, filtered, and
evaporated to yield a red oil (4.85 g). The raw product was purified by
column chromatography (SiO2, EtOAc, or EtOAc/hexane 1/1, first frac-
tion, a red-orange oil crystallized to form a red solid at 4 C; yield: 3.68 g,
65%). Mr (C8H10N2O3) = 182.18 g/mol.
1H NMR (500.32 MHz,
DMSO-d6):δ8.00(d,1H,J=8.71Hz,C 6H3),7.48(d,1H,J=7.1Hz,
C6H3), 7.09 (br, 2H, NH2), 6.67 (t, 1H, J =8 . 4 5H z ,C 6H3), 4.48
(s, 2H, CH2), 3.31 (s, 3H, CH3)p p m .
1-Methoxymethyl-2,3-diaminobenzene (5). A mixture of 4 (1.4 g,
0.008 mol) and 10% Pd/C (0.18 g) in dry EtOH (55 mL) was stirred
under hydrogen atmosphere at room temperature for 18 24 h. The
catalyst was removed by filtration through GF-3-filter under argon and
washed with dry EtOH (50 70 mL). The filtrate was evaporated in
vacuo to give a light-orange solid (1.17 g, 100% yield), which was used
immediatelyinthenextstep.Mr(C8H12N2O)=152.19g/mol.
1HNMR
(500.32 MHz, DMSO-d6):δ 6.52 (dd, 1H, J =1.87 Hz, J= 7.25, C6H3),
6.42 6.36 (m, 2H, C6H3), 4.48 (br, 2H, NH2), 4.31 (br, 4H, NH2+CH2),
3.24 (s, 3H, CH3)p p m .
(1H-Imidazol-1-yl)(1H-pyrazolo[3,4-b]pyridin-3-yl)methanone (6).
N,N0-Carbonyldiimidazole (CDI, 4.16 g, 0.026 mol) was added in small
portions to 1 (2.34 g) in dry DMF (12 mL). The mixture was stirred at
room temperature for 20 24 h. Water (5 mL) then was added and the
suspension was stirred until all CO2 was ceased. The white precipitate
was filtered off, washed with water (3 5 mL), and dried in a sublimator
in vacuo at 60 C, to remove the imidazole as a contaminant. Yield: 1.13 g;
25 29%, based on 3-methyl-1H-pyrazolo[3,4-b]pyridine. Mr (C10H7N5O) =
213.19 g/mol. ESI-MS in methanol (positive): m/z 214 [M+H]
+, 237
[M+Na]
+; (negative): m/z 212 [M H]
 .
1H NMR (500.32 MHz,
DMSO-d6):δ14.95(brs,1H,NH),8.91(s,1H,CHim),8.74(dd,1H,J=
1.61 Hz, J = 4.51 Hz, CHpy), 8.63 (dd, 1H, J = 1.59 Hz,
J = 8.12 Hz, CHpy), 8.14 (t, 1H, J = 1.23 Hz, CHim), 7.51 (dd, 1H, J =
4.46 Hz, J = 8.06 Hz, CHpy), 7.20 (s, 1H, CHim) ppm.
(5-Bromo-1H-pyrazolo[3,4-b]pyridin-3-yl)(1H-imidazol-1-yl)methanone
(7).N,N0-Carbonyldiimidazole(CDI,16.2g,0.1mol)wasaddedinsmall
portions to crude 3 (11.58 g) in dry DMF (70 mL). The mixture was
stirredatroomtemperaturefor20 24h.Water(10mL)thenwasadded
and the suspension was stirred until all CO2 was ceased. The white
precipitate was filteredoff,washedwith water(10 15mL),anddried in
asublimatorinvacuoat60C,toremovetheimidazoleasacontaminant.
Yield: 7.27 g, 13 16%, based on 3-methyl-1H-pyrazolo[3,4-b]-
pyridine. Mr(C10H6BrN5O) = 292.09 g/mol. ESI-MS in methanol
(positive):m/z315[M+Na]
+;(negative):m/z291[M H]
 .
1HNMR
(500.32 MHz, DMSO-d6): δ 14.95 (brs, 1H, NH), 8.89 (s, 1H, CHim),
8.83(d,1H,J =2.12Hz,CHpy), 8.75 (d, 1H, J =2.07Hz,CHpy), 8.13
(s, 1H, CHim), 7.20 (s, 1H, CHim)p p m .
N-(2-Aminophenyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxamide
(8). The solution of 1,2-diaminobenzene (0.5 g, 4.67 mmol) in dry
DMF(2mL)wasaddedtothesuspensionof6 (0.94g,4.41mmol)in
dryDMF(13mL), andthisreactionmixturewasheatedunderargon
at 85 Cf o r5h .D M Ft h e nw a se v a p o r a t e di nv a c u oa t5 0Ca n d
water (10 12 mL) was added. The light-yellow precipitate was
filtered off and dried in vacuo at 50 C. Yield: 0.86 g. The raw
product was used without purification in the next step. Mr-
(C13H11N5O) = 253.26 g/mol. ESI-MS in methanol (positive):
m/z 255 [M+H]
+,2 7 7[ M + N a ]
+; (negative): m/z 253 [M H]
 .
1H NMR (500.32 MHz, DMSO-d6): δ 14.30 (brs, 1H, NHpz), 9.73
(brs, 1H, CONH),8.64(dd,1H,J=1.59Hz,J=4.44Hz,CHpy),8.56
(dd, 1H, J =1 . 5 3H z ,J =8 . 0 2H z ,C Hpy), 7.39 7.36 (m, 2H,
CHpy+CHbz), 6.97 (td, 1H, J =1 . 3 1H z ,J =7 . 7 3H z ,C Hbz), 6.82
(dd, 1H, J =1 . 2H z ,J =7 . 8 9H z ,C Hbz), 6.64 (td, 1H, J =1 . 2H z ,J =
7.67 Hz, CHbz), 4.93 (s, 2H, NH2) ppm.
N-(2-Aminophenyl)-5-bromo-1H-pyrazolo[3,4-b]pyridine-3-car-
boxamide (9). The solution of 1,2-diaminobenzene (0.96 g, 8.88
mmol)indryDMF(10mL)wasaddedtothesuspensionof7(2.28g,
7.8 mmol) in dry DMF (10 mL), and this mixture was heated under
argon at 85 C for 7 h. DMF then was evaporated in vacuo at 50 Ca n d
water(20mL)wasadded.Theyellowprecipitatewasfilteredoffanddried
in vacuo at 50 C. Yield: ∼2.2 g. The raw product was used without
purification in the next step. Mr(C13H10BrN5O) = 332.16 g/mol.
ESI-MS in methanol (positive): m/z 333 [M+H]
+,3 5 5[ M + N a ]
+;
(negative): m/z 331 [M H]
 .
1H NMR (500.32 MHz, DMSO-d6):
δ 14.54(brs,1H,NHpz),9.80 (brs, 1H, CONH),8.73(d,1H,J=2.26
Hz,CHpy),8.69 (d,1H, J=2.22Hz,CHpy),7.34(dd,1H,J=0.98Hz,
J =7.88Hz,CHbz), 6.99 (td, 1H, J =1.43Hz,J =8.03Hz,CHbz),6.82
(dd, 1H, J =1.22Hz,J =7.96Hz,CHbz),6.64(td,1H,J =1.19Hz,J =
7.73 Hz, CHbz), 4.94 (s, 2H, NH2)p p m .
N-[2-Amino-3-(methoxymethyl)phenyl]-5-bromo-1H-pyrazolo-
[3,4-b]pyridine-3-carboxamide (10). Am i x t u r eo f5 (1.17 g, 7.69 mmol)
and 7 (2.1 g, 7.2 mmol) in dry DMF (45 mL) was heated under argon at
85 C for 20 h. DMF then was evaporated in vacuo at 50 C and water
(20 mL) was added. The brown precipitate formed was filtered off and
dried in vacuo at 50 C. Yield: ∼2.3 g. The product was used without
furtherpurificationinthenextstep.Mr(C15H14BrN5O2)=376.21g/mol.
ESI-MSin methanol(positive):m/z 399 [M+Na]
+; (negative):m/z 375
[M H]
 .
1HNMR(500.32MHz,DMSO-d6):δ14.54(brs,1H,NHpz),
9.85 (brs, 1H, CONH), 8.73 (d, 1H, J = 2.13 Hz, CHpy), 8.68 (d, 1H, J =
2.05Hz,CHpy),7.29(d,1H,J=7.56Hz,CHbz),7.03(d,1H,J=7.2 9Hz ,
CHbz), 6.65 (t,1H,J= 7.79 Hz, CHbz),4.78 (brs,2H, NH2), 4.42 (s,2H,
CH2), 3.29 (s, 3H, CH3)p p m .
3-(1H-Benzimidazol-2-yl)-1H-pyrazolo[3,4-b]pyridine(11,L1).The
raw product 8 (0.86 g) was heated in a glacial acetic acid (10 mL) at
125 C for 2.5 h. The solvent was evaporated under reduced pressure
and the residue was dried in vacuo at 50 C, then resuspended in
CH2Cl2/MeOH(4/1,25mL),filteredoff,anddriedinvacuotogiveL1
as a white powder (0.4 g). The filtrate was evaporated and the residue
was purified by column chromatography (SiO2, EtOAc, Rf = 0.58) to
give an additional amount of L1 (0.22 g). Yield: 0.62 g, ∼60% based on
6. Mr (C13H9N5) = 235.24 g/mol. Anal. Calcd for 1130.15H2O30.1
EtOAc (Mr = 246.76 g/mol): C, 65.22; H, 4.13; N, 28.38. Found: C,
65.56; H, 3.90; N, 28.39. ESI-MS in methanol (positive): m/z 237
[M+H]
+, 259 [M+Na]
+; (negative): m/z 235 [M H]
 .U V  vis
(methanol), λmax,n m( ε,M
 1 cm
 1): 232 (25618), 275 (15198),
324 (22333).
1H NMR (500.32 MHz, DMSO-d6): δ 14.19 (brs, 1H,
H1a), 13.11 (brs, 1H, H1b), 8.85 (dd, 1H, J = 1.5 Hz, J = 8.1 Hz, H4a),
8.66 (dd,1H,J=1.5Hz,J=4.5Hz,H6a),7.75(d,1H,J=7.3Hz,H4bor
H7b), 7.54 (d, 1H, J = 7.7 Hz, H4b or H7b), 7.39 (dd, 1H, J = 4.5 Hz, J =
8.0 Hz, H5a), 7.24 (m, 2H, H5b+H6b) ppm.
13C NMR (125.81 MHz,
DMSO-d6):δ153.13(C8a),150.22(C6a),146.99(C2b),144.34(C8bor
C9b), 136.06 (C3a), 134.68 (C8b or C9b), 131.82 (C4a), 123.35 (C5b or
C6b), 122.11 (C5b or C6b), 119.44 (C4b or C7b), 118.65 (C5a), 113.33
(C9a), 112.01 (C4b or C7b) ppm.
15N NMR (50.70 MHz, DMSO-d6):
δ 166.2 (N1a), 121.3 (N1b) ppm.
3-(1H-Benzimidazol-2-yl)-5-bromo-1H-pyrazolo[3,4-b]pyridine (12, L2).
Therawproduct9(2.2g) washeatedinaglacialaceticacid(30mL) at125C
for 2 h. The solvent was evaporated under reduced pressure, and the residue
was dried in vacuo at 50 C, then resuspended in CH2Cl2/MeOH (7/1,
50 mL), filtered off and dried in vacuo to give L2 asawhitepowder(1.15g).
The filtrate was evaporated and the residue was purified by column
chromatography (SiO2, EtOAc/hexane 2/1, Rf = 0.6) to give an additional
amount of the product (0.27 g). Yield: 1.42 g, ∼58% based on 7. Mr-
(C13H8BrN5) = 314.14 g/mol. Anal. Calcd for 1230.25H2O30.04EtOAc
(Mr= 322.17 g/mol): C, 49.06; H, 2.76; N, 21.74. Found: C, 49.44; H, 2.45;
N, 21.59. ESI-MS in methanol (positive): m/z315 [M+H]
+,3 3 7[M + N a ]
+;11718 dx.doi.org/10.1021/ic201704u |Inorg. Chem. 2011, 50, 11715–11728
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(negative): m/z 313 [M H]
 .U V  vis (methanol), λmax,n m
(ε,M
 1 cm
 1): 234 (28154), 282 (17628), 335 (17198).
1HN M R
(500.32 MHz, DMSO-d6): δ 14.43 (brs, 1H, H1a), 13.19 (brs, 1H,
H1b),8.99(d,1H,J =2.2Hz,H 4a),8.75(d,1H,J =2.3Hz,H 6a),7.77
(d, 1H, J =7 . 9H z ,H 4b or H7b), 7.54 (d, 1H, J =7 . 9H z ,H 4b or H7b),
7.26(m,2H,H5b+H6b)ppm.
13CNMR(125.81MHz,DMSO-d6):δ
151.49 (C8a), 150.66 (C6a), 146.42 (C2b), 144.24 (C8b or C9b),
135.61 (C3a), 134.67 (C8b or C9b), 133.35 (C4a), 123.54 (C5b or
C6b),122.27(C5b orC6b),119.55(C4borC7b),114.87(C5a orC9a),
113.49 (C5a or C9a), 112.09 (C4b or C7b)p p m .
15NN M R( 5 0 . 7 0
MHz, DMSO-d6): δ 167.5 (N1a), 121.3 (N1b)p p m .
5-Bromo-3-(4-methoxymethyl-1H-benzimidazol-2-yl)-1H-pyrazolo-
[3,4-b]pyridine (13, L3). The raw product 10 (2.3 g) was heated in a
glacial aceticacid (40mL)at125C for2h.Thesolventwasevaporated
under reduced pressure, and the residue dried in vacuo at 50 C. After
washingwithCH2Cl2(30mL),CH2Cl2/MeOH(2/1,5 7mL)thegray
product was purified by column chromatography (SiO2, EtOAc, Rf =
0.68) to give a white powder (0.9 g). The filtrates were evaporated and
the remaining solid was purified by column chromatography to give an
additional amount of the product (0.3 g). Yield: 1.2 g, 47%, based on 7.
Mr(C15H12BrN5O) = 358.19 g/mol. Anal. Calcd for 13: C, 50.29; H,
3.38; N, 19.55. Found: C, 50.03; H, 3.19; N, 19.19. ESI-MS in methanol
(positive): m/z 381 [M+Na]
+; (negative): m/z 357 [M H]
 .U V  vis
(methanol), λmax,n m( ε,M
 1 cm
 1): 235 (29776), 282 (17544), 337
(16958).
NMR characterization of 7b-L3 and 4b0-L3 tautomers (1/1.3) in
DMSO-d6:
1H NMR (500.32 MHz, DMSO-d6), 7b-L3: δ 14.47 (brs,
1H,H1a),13.25(brs,1H,H1b),8.99or8.98(d+d,(1+1.3)H,J=2.3Hz,
H4a+H4a0), 8.75 (d, (1 + 1.3)H, J = 2.3 Hz, H6a+H6a0), 7.72 (dd, 1H, J =
1.8 Hz, J = 6.8 Hz, H4b), 7.28 7.21 (m, (2 + 2.6)H, H5a,H 6a+H5a0,
H6a0), 4.80 (s, 2H, H10b), 3.37 (s, 3H, H11b) ppm.
1H NMR (500.32
MHz, DMSO-d6), 4b0-L3: δ 14.43 (brs, 1.3H, H1a0), 13.22 (brs, 1.3H,
H1b0),8.99or8.98(d+d,(1+1.3)H,J=2.3Hz,H4a+H4a0),8.75(d,(1+
1.3)H, J = 2.3 Hz, H6a+H6a0), 7.47 (dd, 1.3H, J = 1.2 Hz, J = 7.7 Hz,
H7b0), 7.28 7.21 (m, (2 + 2.6)H, H5a,H 6a+H5a0,H 6a0), 4.96 (s, 2.6H,
H10b0), 3.44 (s, 3.9H, H11b0) ppm.
13C NMR (125.81 MHz, DMSO-d6),
7b-L3: δ 151.51 (C8a+C8a0), 150.69 (C6a or C6a0), 150.65 (C6a or C6a0),
146.70 (C2b), 144.46 (C9b), 135.62 (C3a+C3a0), 133.45 (C4a or C4a0),
133.42 (C4a or C4a0), 133.29 (C8b), 123.38 (C6b;C 5b or C6b0), 123.36
(C6b;C 5b or C6b0), 122.95 (C7b), 122.16 (C5b or C6b0), 118.97 (C4b),
115.04 (C5a or C9a or C5a0 or C9a0), 114.92 (C5a or C9a or C5a0 or C9a0),
113.49(C5aorC9aorC5a0 orC9a0),70.49(C10b),57.95(C11b)ppm.
13C
NMR (125.81 MHz, DMSO-d6), 4b0-L3: δ 151.51 (C8a+C8a0), 150.69
(C6aorC6a0),150.65(C6aorC6a0),146.13(C2b0),142.50(C9b0),135.62
(C3a+C3a0), 134.42 (C8b0), 133.45 (C4a or C4a0), 133.42 (C4a or C4a0),
129.38 (C4b0), 123.38 (C6b;C 5b or C6b0), 123.36 (C6b;C 5b or C6b0),
122.16 (C5b or C6b0),120.81 (C5b0),115.04 (C5a or C9a or C5a0 or C9a
0),
114.92 (C5a or C9a or C5a0 or C9a0), 113.49 (C5a or C9a or C5a0 or C9a
0),
111.17(C7b0),69.90(C10b0),58.35(C11b0)ppm.
15NNMR(50.70MHz,
DMSO-d6): δ 167.6 (N1a+N1a0), 121.4 (N1b+N1b0) ppm.
Synthesis of Organometallic Complexes. (η
6-p-Cymene){3-
(1H-benzimidazol-kN-2-yl)-1H-pyrazolo-kN-[3,4-b]pyridine}chlorid-
oruthenium(II) chloride, [Ru
IICl(η
6-p-cymene)(L1)]Cl, (11a). A mix-
ture of L1 (54.7 mg, 0.23 mmol) and [RuCl2(η
6-p-cymene)]2 (70 mg,
0.11 mmol) in dry ethanol (25 mL) was stirred at room temperature for
1 h. Ethanol then was evaporated up to ca. 3 mL and dry Et2O (40 mL)
was added. The yellow precipitate was filtered off and dried in vacuo at
50C.Yield:90 95mg,70 74%as11a3H2O.Mr(C23H23Cl2N5Ru)=
541.44g/mol.Anal.Calcdfor11a3H2O(Mr=559.45g/mol):C,49.38;
H, 4.50; N, 12.52; Cl, 12.67. Found: C, 49.68; H, 4.25; N, 12.11; Cl,
12.26. ESI-MS in methanol (positive): m/z 470 [M HCl Cl]
+, 507
[M Cl]
+,528[M HCl+Na]
+;(negative):m/z468[M 2HCl H]
 ,
505 [M HCl H]
 .U V  vis (methanol), λmax,n m( ε,M
 1 cm
 1):
251 (16335), 299 (26663), sh 347 (16012). UV vis (H2O), λmax,n m
(ε,M
 1 cm
 1): sh 245 (10728), 294 (18597), 360 (9666).
1HN M R
(500.32 MHz, DMSO-d6): δ 14.91 (brs, 1H, H1b), 9.17 (d, 1H, J =7 . 7
Hz, H4a), 8.82 (d, 1H, J =3 . 8H z ,H 6a), 8.11 (d, 1H, J =7 . 1H z ,H 4b),
7.84 (d, 1H, J =8 . 5H z ,H 7b), 7.58 (m, 3H, H5a+H5b+H6b), 6.43 (m,
2H,H2c+H6c), 6.31(d, 1H,J =5.3Hz,H 3corH5c),6.12(d,1H,J=5.5
Hz, H3c or H5c), 2.54 (sep, 1H, H7c,u n d e rD M S O - d6 peak), 2.21 (s,
3H,H10c),0.94 (d, 3H, J =6.6Hz,H 8corH9c),0.91(d,3H,J =6.6Hz,
H8c or H9c) ppm.
13C NMR (125.81 MHz, DMSO-d6): δ 153.97
(C8a),150.45(C6a),146.52(C2b),141.37(C9b),134.70(C8b),134.64
(C3a), 131.48 (C4a), 125.39 (C5b or C6b), 124.92 (C5b or C6b), 119.56
(C5a),117.85 (C4b), 113.96 (C7b), 111.54 (C9a),103.96(C4c),103.74
(C1c),84.44(C2corC6c),83.73(C2corC6c),82.15(C3corC5c),80.84
(C3c or C5c), 31.12 (C7c), 22.19 (C8c+C9c), 19.17 (C10c) ppm.
15N
NMR (50.70 MHz, DMSO-d6): δ 128.7 (N1b) ppm.
(η
6-p-Cymene){3-(1H-benzimidazol-kN-2-yl)-1H-pyrazolo-kN-
[3,4-b]pyridine}chloridoosmium(II) chloride, [Os
IICl(η
6-p-cymene)-
(L1)]Cl, (11b). A mixture of L1 (42.5 mg, 0.18 mmol) and [OsCl2-
(η
6-p-cymene)]2(70mg,0.09mmol)indryethanol(25mL)wasstirred
at room temperature for 2 h. Ethanol then was removed under reduced
pressure up to ca. 3 mL and dry Et2O (40 mL) was added. The yellow
precipitatewasfilteredoffanddriedinvacuoat50C.Yield:93mg,81%
as 11b3H2O. Mr(C23H23Cl2N5Os) = 630.59 g/mol. Anal. Calcd for
11b3H2O( Mr = 648.61 g/mol): C, 42.59; H, 3.88; N, 10.79. Found: C,
42.56; H, 3.57; N, 10.97. ESI-MS in methanol (positive): m/z
[M HCl Cl]
+, 596 [M Cl]
+, 618 [M HCl+Na]
+; (negative): m/z
595 [M HCl H]
 .U V  vis (methanol), λmax,n m( ε,M
 1 cm
 1): sh
252 (17048), 299 (20228), 343 (19879).
1H NMR (500.32 MHz,
MeOH-d4):δ8.99(dd,1H,J=1.3Hz,J=8.1Hz,H4a),8.77(dd,1H,J=
1.4 Hz, J = 4.8 Hz, H6a), 7.96 (dd, 1H, J = 2.0 Hz, J = 6.4 Hz, H4b), 7.80
(dd,1H,J=1.9Hz,J=6.1Hz,H7b),7.64 7.59(m,3H,H5a+H5b+H6b),
6.66(d,1H,J=5.6Hz,H2corH6c),6.59(d,1H,J=5.7Hz,H2corH6c),
6.43(d,1H,J=5.6Hz,H3corH5c),6.21(d,1H,J=5.7Hz,H3corH5c),
2.43 (sep, 1H, J = 6.9 Hz, H7c), 2.38 (s, 3H, H10c), 0.96 (d, 3H, J = 6.9
Hz, H8c or H9c), 0.92 (d, 3H, J = 6.9 Hz, H8c or H9c) ppm.
13C NMR
(125.81 MHz, MeOH-d4): δ 153.25 (C8a), 148.91 (C2b), 147.42 (C6a),
140.49 (C9b), 135.15 (C3a), 134.25 (C8b), 132.07 (C4a), 125.47 (C5b or
C6b), 124.81 (C5b or C6b), 118.48 (C5a), 116.89 (C4b), 112.98 (C7b),
112.92(C9a),97.71(C4c),94.88(C1c),76.44(C2corC6c),74.99(C2cor
C6c), 71.93 (C3c or C5c), 70.44 (C2c or C6c), 31.37 (C7c), 21.35 (C8c or
C9c), 21.09 (C8c or C9c), 17.84 (C10c) ppm. Crystals of 11b34H2O
suitable for XRD study have been obtained from a solution of 11b in
ethanol.
(η
6-p-Cymene){3-(1H-benzimidazol-kN-2-yl)-5-bromo-1H-pyrazo-
lo-kN-[3,4-b]pyridine}chloridoruthenium(II) chloride, [Ru
IICl(η
6-p-
cymene)(L2)]Cl, (12a). A mixture of L2 (73.2 mg, 0.23 mmol) and
[RuCl2(η
6-p-cymene)]2 (70 mg, 0.11 mmol) in dry ethanol (25 mL)
was stirred at room temperature for 1 h. Ethanol then was removed
underreducedpressureuptoca.2mLanddryEt2O(40mL)wasadded.
Theyellowprecipitatewasfilteredoffanddriedinvacuoat40C.Yield:
106 mg, 73% as 12a3H2O. Mr(C23H22BrCl2N5Ru) = 620.33 g/mol.
Anal. Calcd for 12a3H2O( Mr = 638.35 g/mol): C, 43.28; H, 3.79; N,
10.97. Found: C, 43.42; H, 3.54; N, 11.18. ESI-MS in methanol
(positive): m/z 548 [M HCl Cl]
+, 608 [M HCl+Na]
+; (negative):
m/z 549 [M 2HCl H]
 , 582 [M HCl H]
 .U V  vis (methanol),
λmax,nm(ε,M
 1cm
 1):sh254(17778),303(29953),351(17387).
1H
NMR (500.32 MHz, DMSO-d6): δ 14.34 (brs, 1H, H1b), 9.21 (s, 1H,
H4a),8.73(s,1H,H6a),8.06(d,1H,J=7.6Hz,H4b),7.79(d,1H,J=8.5
Hz, H7b), 7.52 (m, 2H, H5b+H6b), 6.32 (d, 2H, J = 5.8 Hz, H2c+H6c),
6.22(d,1H,J=6.2Hz,H3corH5c),6.03(d,1H,J=6.1Hz,H3corH5c),
2.52 (sep, 1H, H7c, under DMSO-d6 peak), 2.18 (s, 3H, H10c), 0.94 (d,
3H,J=6.8Hz,H8corH9c),0.89(d,3H,J=6.9Hz,H8corH9c)ppm.
13C
NMR (125.81 MHz, DMSO-d6): δ 154.04 (C8a), 151.24 (C6a), 146.57
(C2b), 141.37 (C9b), 134.63 (C8b), 133.43 (C3a), 131.82 (C4a), 125.33
(C5b or C6b), 124.88 (C5b or C6b), 117.78 (C4b), 114.72 (C5a or C9a),11719 dx.doi.org/10.1021/ic201704u |Inorg. Chem. 2011, 50, 11715–11728
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113.85 (C7b), 112.48 (C5a or C9a), 103.96 (C4c), 103.74 (C1c), 84.44
(C2c orC6c),83.69(C2c orC6c), 82.16(C3c or C5c),80.76(C3c or C5c),
31.09 (C7c), 22.20 (C8c or C9c), 22.17 (C8c or C9c), 19.16 (C10c) ppm.
15N NMR (50.70 MHz, DMSO-d6): δ 127.3 (N1b) ppm.
(η
6-p-Cymene){3-(1H-benzimidazol-kN-2-yl)-5-bromo-1H-pyrazolo-
kN-[3,4-b]pyridine}chloridoosmium(II) chloride, [Os
IICl(η
6-p-cymene)-
(L2)]Cl,(12b).AmixtureofL2(56.4mg,0.18mmol)and[OsCl2(η
6-p-
cymene)]2 (70 mg, 0.09 mmol) in dry ethanol (25 mL) was stirred at
room temperature for 2 h. Ethanol then was removed under reduced
pressure up to ca. 3 mL and dry Et2O (40 mL) was added. The yellow
precipitate was filtered off and dried in vacuo at 50 C. Yield: 102 mg,
79% as 12b3H2O. Mr(C23H22BrCl2N5Os) = 709.49 g/mol. Anal.
Calcdfor12b3H2O( Mr =727.51g/mol):C,37.97;H,3.33;N,9.63.
Found: C, 37.82; H, 3.02; N, 9.33. ESI-MS in methanol (positive):
m/z 638 [M HCl Cl]
+, 696 [M HCl+Na]
+; (negative): m/z 672
[M HCl H]
 .U V  vis (methanol), λmax,n m( ε,M
 1 cm
 1): sh 253
(21638), 302 (30505), 357 (21813).
1H NMR (500.32 MHz, MeOH-
d4): δ 9.08 (d, 1H, J = 2.1 Hz, H4a), 8.84 (d, 1H, J = 2.1 Hz, H6a), 7.96
(dd, 1H, J = 2.1 Hz, J = 6 Hz, H4b), 7.80 (dd, 1H, J = 2.1 Hz, J = 6.1 Hz,
H7b), 7.63 (m, 2H, H5b+H6b), 6.69 (d, 1H, J = 5.7 Hz, H2c or H6c), 6.63
(d,1H,J=5.6Hz,H2corH6c),6.48(d,1H,J=5.6Hz,H3corH5c),6.22
(d, 1H, J = 5.7 Hz, H3c or H5c), 2.42 (sep, 1H, J = 6.9 Hz, H7c), 2.39 (s,
3H, H10c), 0.95 (d, 3H, J = 6.9 Hz, H8c or H9c), 0.91 (d, 3H, J = 6.9 Hz,
H8c or H9c)ppm.
13C NMR (125.81 MHz, MeOH-d4): δ 153.04 (C8a),
152.49 (C6a), 148.15 (C2b), 140.47 (C9b), 134.58 (C3a), 134.19 (C8b),
131.13 (C4a), 125.79 (C5b or C6b), 125.05 (C5b or C6b), 116.99 (C4b),
115.39 (C5a or C9a), 113.09 (C7b), 112.11 (C5a or C9a), 98.54 (C4c),
95.52 (C1c), 75.73 (C2c or C6c), 75.25 (C2c or C6c), 71.87 (C3c or C5c),
69.99 (C3c or C5c), 31.41 (C7c), 21.34 (C8c or C9c), 21.16 (C8c or C9c),
17.84 (C10c) ppm. Crystals of 12b and 12b32CH3OH32H2O suitable
for XRD study have been obtained from a solution of 12b in methanol.
(η
6-p-Cymene){5-bromo-3-(7-methoxymethyl-1H-benzimidazol-
kN-2-yl)-1H-pyrazolo-kN-[3,4-b]pyridine}chloridoruthenium(II)chloride,
[Ru
IICl(η
6-p-cymene)(L3)]Cl, (13a). A mixture of L3 (64 mg, 0.18
mmol) and [RuCl2(η
6-p-cymene)]2 (50 mg, 0.08 mmol) in dry ethanol
(25 mL) was stirred at room temperature for 1 h. Ethanol then was
removed under reduced pressure up to ca. 3 mL and dry Et2O (40 mL)
was added. The yellow precipitate was filtered off and dried in vacuo at
50C.Yield:95.8mg,85%as13a31.5H2O.Mr(C25H26BrCl2N5ORu)=
664.39 g/mol. Anal. Calcd for 13a31.5H2O( Mr = 691.41 g/mol): C,
43.43; H, 4.23; N, 10.13; Cl, 10.26. Found: C, 43.81; H, 4.24; N, 10.11;
Cl, 10.57. ESI-MS in methanol (positive): m/z 592 [M HCl Cl]
+,
650 [M HCl+Na]
+; (negative): m/z 591 [M 2HCl H]
 , 628
[M HCl H]
 .U V  vis (methanol), λmax,n m( ε,M
 1cm
 1): sh 252
(18744), 306 (28529), 354 (16889).
1H NMR (500.32 MHz, DMSO-
d6):δ13.88(brs,1H,H1b),9.41(s,1H,H4a),8.68(s,1H,H6a),7.99(d,
1H, J = 7.7 Hz, H4b), 7.49 (m, 2H, H5b+H6b), 6.29 (m, 2H, H2c+H6c),
6.20(d,1H,J=5.5Hz,H3corH5c),6.00(d,1H,J=5.9Hz,H3corH5c),
4.88(s,2H,H10b),3.39(s,3H,H11b),2.48(sep,1H,H7c,underDMSO-
d6peak),2.17(s,3H,H10c),0.93(d,3H,J=6.9Hz,H8corH9c),0.87(d,
3H,J=6.8Hz,H8corH9c)ppm.
13CNMR(125.81MHz,DMSO-d6):δ
155.35 (C8a), 150.27 (C6a), 147.43 (C2b), 141.64 (C9b), 133.07 (C8b),
132.68 (C3a), 131.68 (C4a), 124.87 (C5b or C6b), 124.59 (C5b or C6b),
124.53 (C7b), 117.18 (C4b), 114.23 (C5a or C9a), 112.78 (C5a or C9a),
103.74 (C4c), 103.09 (C1c), 85.38 (C2c or C6c), 83.68 (C2c or C6c),
82.13(C3corC5c),81.05(C3corC5c),70.19(C10b),58.03(C11b),31.04
(C7c), 22.22 (C8c or C9c), 22.09 (C8c or C9c), 19.13 (C10c) ppm.
15N
NMR (50.70 MHz, DMSO-d6): δ 122.9 (N1b) ppm. The red XRD-
qualitycrystals of[Ru
IICl(η
6-p-cymene)(L3 H)] (13c)wereobtained
from EtOH/Et2O and an EtOH solution of 13a (long crystallization).
The yellow crystals of [Ru
IICl(η
6-p-cymene)(L3)]Cl3[Ru
IICl(η
6-p-
cymene)(L3 H)]3CH3OH (13d3CH3OH) suitable for XRD study
have been obtained from methanolic solution of 13a (short crystal-
lization).
1HN M R( 13c, 500.32 MHz, DMSO-d6): δ 13.43 (s, 1H),
9.18(d,1H,J=2.1Hz),8.48(d,1H,J=2.2Hz),7.94(d,1H,J=8.2Hz),
7.45(t,1H,J=7.8Hz),7.39(d,1H,J=7.2Hz),6.16(d,1H,J=6.0Hz),
6.13(d,1H,J=6.1Hz),6.07(d,1H,J=5.9Hz),5.89(d,1H,J=6.4Hz),
4.85(s,2H),4.04(s,3H),2.14(s,3H),0.93(d,3H,J=6.8Hz),0.86(d,
3H, J = 6.9 Hz) ppm.
(η
6-p-Cymene){5-bromo-3-(7-methoxymethyl-1H-benzimidazol-
kN-2-yl)-1H-pyrazolo-kN-[3,4-b]pyridine}chloridoosmium(II) chloride,
[Os
IICl(η
6-p-cymene)(L3)]Cl, (13b). Am i x t u r eo fL3 (59 mg, 0.17
mmol) and [OsCl2(η
6-p-cymene)]2 (60 mg, 0.08 mmol) in dry ethanol
(25 mL) was stirred at room temperature for 3 h. Ethanol was
evaporated up to ca. 3 mL and dry Et2O( 4 0m L )w a sa d d e d .T h e
yellow precipitate was filtered off and dried in vacuo at 50 C. Yield: 80
mg, 70%. Mr(C25H26BrCl2N5OOs) = 753.55 g/mol. Anal. Calcd for
13b: C, 39.85; H, 3.48; N, 9.29. Found: C, 39.60; H, 3.32; N, 9.20. ESI-
MS in methanol (positive): m/z 682 [M HCl Cl]
+, 704 [M 2HCl
+Na]
+; (negative): m/z 680 [M 2HCl H]
 , 716 [M HCl H]
 .
UV vis (methanol), λmax,n m( ε,M
 1 cm
 1): sh 256 (19825), 303
(24634), 357 (18850).
1H NMR (500.32 MHz, MeOH-d4): δ 9.33 (d,
1H, J = 2.1 Hz, H4a), 8.84 (d, 1H, J = 2.2 Hz, H6a), 7.91 (dd, 1H, J = 1.2
Hz, J = 7.8 Hz, H4b), 7.64 7.58 (m, 2H, H5b+H6b), 6.69 (d, 1H, J = 5.6
Hz,H2corH6c),6.62(d,1H,J=5.7Hz,H2corH6c),6.47(d,1H,J=5.5
Hz,H3corH5c),6.21(d,1H,J=5.6Hz,H3corH5c),4.94(q,2H,J=12.4
Hz, H10b), 3.49 (s, 3H, H11b), 2.41 (sep, 1H, J = 6.9 Hz, H7c), 2.39 (s,
3H, H10c), 0.94 (d, 3H, J = 6.9 Hz, H8c or H9c), 0.89 (d, 3H, J = 6.9 Hz,
H8c or H9c) ppm.
13C NMR (125.81 MHz, MeOH-d4):δ 153.18 (C8a),
152.16 (C6a), 148.36 (C2b), 140.82 (C9b), 134.35 (C3a), 132.68 (C8b),
131.68 (C4a), 125.63 (C5b or C6b), 124.85 (C5b or C6b), 124.51 (C7b),
116.72 (C4b), 115.24 (C5a or C9a), 112.26 (C5a or C9a), 98.75 (C4c),
95.50 (C1c), 75.98 (C2c or C6c), 75.34 (C2c or C6c), 71.82 (C3c or C5c),
70.29 (C10b), 70.04 (C3c or C5c), 57.17 (C11b), 31.39 (C7c), 21.34 (C8c
or C9c), 21.16 (C8c or C9c), 17.85 (C10c) ppm. The yellow crystals of
[Os
IICl(η
6-p-cymene)(L3)]Cl3[Os
IICl(η
6-p-cymene)(L3 H)]30.75
CH3OH30.25H2O( 13e30.75CH3OH30.25H2O) suitable for XRD
study have been obtained from a methanolic solution of 13b.
Physical Measurements. Elemental analyses (C, H, N, Cl) were
performed by the Microanalytical Service of the Institute of Physical
Chemistry, University of Vienna. Electrospray ionization mass spectro-
metry (ESI-MS) was carried out with an Esquire 3000 instrument
(BrukerDaltonics,Bremen,Germany),usingsolutionsofcompoundsin
methanol. The expected and measured isotope distributions were
compared. UV vis spectra were recorded on a Lambda 20 UV vis
spectrophotometer (Perkin Elmer), using samples dissolved in metha-
nol (L1 L3, 11a, 12a, 13a, 11b, 12b, 13b) and water (11a) over 24
or 48 h, correspondingly. The one-dimensional (
1H,
13C,
15N) and
two-dimensional spectra (
15N,
1HH S Q C ,
13C,
1HH S Q C ,
13C,
1H
HMBC,
1H,
1H COSY,
1H,
1HT O C S Y ,
1H,
1HN O E S Y( L3, 12a),
1H,
1HROESY(L3,11a,12a,13a,13b))wererecordedwithaBruker
Model DPX500 (Ultrashield Magnet) system in DMSO-d6 (L1 L3,
11a,12a,13a),MeOH-d4(11b,12b,13b),D2O(
1HNMR,11a),and
D2O/DMSO-d6 (
1HN M R ,12a), using standard pulse programs at
500.32 (
1H), 125.81 (
13C) and 50.70 (
15N) MHz.
1Hs i g n a l sa r e
referenced relative to the solvent signals (DMSO-d6 at 2.51, MeOH-d4
at 3.33 ppm).
Crystallographic Structure Determination. XRD measure-
ments were performed on a Bruker Model X8 APEXII CCD diffract-
ometer. Single crystals were positioned at distances of 35, 40, 40, 40, 40,
40, and 35 mm from the detector, and 1556, 1131, 518, 1911, 1176,
1978,and1039framesweremeasured,eachfor30,60,30,20,70,60,and
30sover1scanwidthfor230.5H2O,11b34H2O,12b,12b32CH3OH3
2H2O, 13c, 13d3CH3OH, and 13e30.75CH3OH30.25H2O, corre-
spondingly. The data were processed using SAINT software.
39 Crystal
data, data collection parameters, and structure refinement details are
given in Table 1. The structures were solved by direct methods and
refined by full-matrix least-squares techniques. Non-H atoms were11720 dx.doi.org/10.1021/ic201704u |Inorg. Chem. 2011, 50, 11715–11728
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refinedwith anisotropicdisplacement parameters.H atoms wereinserted
incalculatedpositions and refinedwitharidingmodel. Refinementofthe
structure of 12b revealed that the chloride counteranion occupies two
statisticallydisorderedpositionswithsiteoccupationfactor(sof)valuesof
0.57:0.43, whereas, in 13c, the methoxymethylene groupwas found to be
disordered over two positions with sof values of 0.80:0.20. Similarly, the
methoxymethylene group of one crystallographically independent com-
plex in 13d3CH3OH or in both crystallographically independent com-
plexes in 13e30.75CH3OH30.25H2O is disordered with sof values of
0.35:0.65 and 0.60:0.40, 0.80:0.20, correspondingly. The disorder was
resolved with constrained anisotropic displacement parameters and
restrained bond distances using EADP and SADI instructions of
SHELX97, respectively. Structure solution was achieved with SHELXS-97
andrefinementwithSHELXL-97,
40andgraphicswereproducedwith
ORTEP-3.
41
Cell Lines and Culture Conditions. A549 (non-small cell lung
carcinoma, human) and SW480 (colon carcinoma, human) cells were
kindly provided by Brigitte Marian (Institute of Cancer Research,
Department of Medicine I, Medical University of Vienna, Austria).
CH1 cells (ovarian cancer, human) were a gift from Lloyd R. Kelland
(CRC Centre for Cancer Therapeutics, Institute of Cancer Research,
Sutton, U.K.). All cell culture media and supplements were purchased
from Sigma Aldrich. Cells were grown in 75-cm
2 culture flasks (Iwaki)
in a complete medium (i.e., Minimum Essential Medium supplemented
with 10% heat-inactivated fetal bovine serum, 1 mM sodium pyruvate,
4m ML-glutamine, and 1% nonessential amino acids from 100  stock)
as adherent monolayer cultures. Cultures were grown at 37 C under a
humidified atmosphere containing 5% CO2 and 95% air.
Inhibition of Cancer Cell Growth. Antiproliferative activity in
vitro was determined by the colorimetric MTT assay (MTT = 3-(4,5-
dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide, Fluka). For
this purpose, cells were harvested from culture flasks by the use of
trypsin and seeded in complete medium (100 μL/well) into 96-well
plates (Iwaki) in densities of 4   10
3 (A549), 1.5   10
3 (CH1), and
2.5   10
3 (SW480) viable cells per well. Cells were allowed for 24 h to
settle and resume proliferation. Test compounds were dissolved in
DMSO first, appropriately diluted in complete medium, and instantly
added to the plates (100 μL/well), where the DMSO content did not
exceed 0.4% and 1% for the ligands and complexes, respectively. After
exposure for 96 h, the medium was replaced with 100 μL/well RPMI
1640 medium (supplemented with 10% heat-inactivated fetal bovine
serum and 4 mM L-glutamine) plus 20 μL/well MTT solution in
phosphate-buffered saline (5 mg/mL), followed by incubation for 4 h.
Subsequently,themedium/MTTmixturewasremoved,andtheformazan
product formed by viable cells was dissolved in DMSO (150 μL/well).
Opticaldensities weremeasuredwith a microplatereader(TecanSpectra
Classic) at 550 nm (and a reference wavelength of 690 nm) to yield
relative quantities of viable cells as percentages of untreated controls, and
50% inhibitory concentrations (IC50) were interpolated from concentra-
tion effect curves. Calculations are based on at least three independent
experiments with triplicates for each concentration level.
Cell Cycle Analyses. To study the effects on the cell cycle of
exponentially growing CH1 cells by flow cytometric analysis of their
relativeDNAcontent,cellswereharvestedfromcultureflasks,seededin
complete medium into 90-mm Petri dishes (1   10
6 cells/dish) and,
after recovery for 24 h, exposed to various concentrations of the test com-
pounds for 24 h. For this purpose, test compounds were diluted from
DMSO stocks with complete medium (see above) such that the effective
DMSO content did not exceed 0.5%. After exposure, treated and control
cells were collected by scratching, washed with PBS, and stained with
5μg/mLpropidiumiodideovernight.Theirfluorescencewasmeasuredwith
a FACS Calibur instrument (Becton Dickinson), and the obtained histo-
grams were analyzed with Cell Quest Pro software (BectonDickinson).
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At least two independent experiments were performed for each setting,
and 2.5 or 3.0   10
4 cells were measured per sample.
Kinase Assay. The Cdk-inhibitory capacities of test compounds
werestudiedbyaradiochemicalassayusingrecombinantCdk1/cyclinB
and Cdk2/cyclin E isolated from Sf21 insect cells and histone H1 as the
substrate for phosphorylation, as described by Marko et al.
42 Briefly,
MOPS-buffered assay mixtures containing the test compound (with a
maximum of 1% DMSO), the respective kinase/cyclin complex, histone
H1, and 0.4 μCi (γ-
32P)ATP per sample were incubated for 10 min at
30 C. Aliquots of the solution were spotted onto phosphocellulose
squares,whichhadbeenwashedthreetimeswith0.75%phosphoricacid,
followed by acetone. The dried squares were measured in scintillation
vials by β-counting (Perkin Elmer Tri-Carb 2800TR; Quanta Smart
software).Resultswereobtainedinduplicateinatleasttwoindependent
experiments, and IC50 values were calculated by interpolation.
’RESULTS AND DISCUSSION
Synthesis of Ligands and Complexes. Several routes to 3-
(1H-benzimidazol-2-yl)-1H-pyrazolo[3,4-b]pyridines have been
proposed by Johnson & Johnson Pharmaceutical Research &
Development L.L.C. The first one was developed for 3-(1H-
benzimidazol-2-yl)-1H-pyrazolo[3,4-b]pyridines with an un-
substituted benzimidazole moiety and involved sulfur-induced
benzimidazoleringformationviathetreatmentof5-bromo-1H-
pyrazolo[3,4-b]pyridine-3-carboxaldehyde with 1,2-diamino-
benzene.
22Thepoorreproducibilityofthissynthesispromptedthe
exploration of an alternative way, via 5-bromo-1H-pyrazolo[3,4-
b]pyridine-3-carboxylic acid, which was used for the preparation of
3-(1H-benzimidazol-2-yl)-1H-pyrazolo[3,4-b]pyridines with a sub-
stituted benzimidazole moiety.
The patented route to 5-bromo-1H-pyrazolo[3,4-b]pyridine-3-
carboxylic acid (3) consists of four steps (see Scheme 1, steps
i iv): oxidation of 3-methyl-1H-pyrazolo[3,4-b]pyridine by
KMnO4 in the presence of a base with subsequent acidiﬁcation
with H2SO4,
35 esteriﬁcation of 1H-pyrazolo[3,4-b]pyridine-3-car-
boxylic acid (1) in the presence of H2SO4 in methanol,
35
bromination of 1H-pyrazolo[3,4-b]pyridine-3-carboxylic acid
methyl ester in an AcOH/AcONa mixture,
23 and hydrolysis of
5-bromo-1H-pyrazolo[3,4-b]pyridine-3-carboxylicacidmethyles-
terinthepresenceofNaOH,followedbyacidiﬁcationwithHCl.
23
The overall yield of 5-bromo-1H-pyrazolo[3,4-b]pyridine-3-car-
boxylic acid (3) was 18%.
We performed the synthesis of 3 in two steps (see Scheme 1,
steps v and vi): bromination of 3-methyl-1H-pyrazolo[3,4-b]-
pyridine in AcOH/AcONa mixture and oxidation of crude
5-bromo-3-methyl-1H-pyrazolo[3,4-b]pyridine (2)b yK M n O 4
in a basic medium, followed by acidiﬁcation with 37% HCl, with
an overall yield of 24 35%. 5-Bromo-3-methyl-1H-pyrazolo-
[3,4-b]pyridine(2)isaknowncompound,thesynthesisofwhich
is well-documented.
43 45
For the benzimidazole ring formation, 1,2-diaminobenzene
and 1-methoxymethyl-2,3-diaminobenzene have been used. The
reported synthesis of 1-methoxymethyl-2,3-diaminobenzene (5)
from 2,3-diaminobenzyl alcohol aﬀorded the desired product in
34% yield (see Scheme 2, step i).
23 However, the instability and
lowyieldofdiamines,aswellasthenecessitytopurifythedesired
ether using column chromatography, stimulated the search for a
more-convenient procedure that was subsequently proposed:
etheriﬁcation of 2-amino-3-nitrobenzyl alcohol, followed by the
reductionof1-methoxymethyl-2-amino-3-nitrobenzene(4)with
10%Pd/Cinethanolunderahydrogenatmosphereaﬀorded5in
65 75% yield (see Scheme 2, steps ii and iii).
Patented benzimidazole ring formation by cyclization of the
3-carboxyl group of 5-bromo-1H-pyrazolo[3,4-b]pyridine-3-car-
boxylic acid (3) with substituted 1,2-diaminobenzenes was
realized via amide formation using coupling reagents, followed
by treatment with glacial acetic acid.
21 HATU (N,N,N0,N0-
tetramethyl-O-(7-azabenzotriazol-1-yl)uronium hexaﬂuoro-
phosphate) was used as a coupling reagent.
21,23
Three 3-(1H-benzimidazol-2-yl)-1H-pyrazolo[3,4-b]pyridines
(L1 L3) (where X = H, Br; and Y = H, CH2OCH3)h a v eb e e n
synthesized in this work (see Chart 1): 3-(1H-benzimidazol-2-yl)-
1H-pyrazolo[3,4-b]pyridine (L1) is a new compound that we have
prepared as a model ligand for coordination to metals; 3-(1H-
benzimidazol-2-yl)-5-bromo-1H-pyrazolo[3,4-b]pyridine (L2)w a s
previously known as BOC-protected compound prepared via
5-bromo-1H-pyrazolo[3,4-b]pyridine-3-carboxaldehyde;
23 5-bro-
mo-3-(4-methoxymethyl-1H-benzimidazol-2-yl)-1H-pyrazolo[3,4-b]-
pyridine (L3) was synthesized via 5-bromo-1H-pyrazolo[3,4-b]-
pyridine-3-carboxylic acid (3) and patented as a potential Cdk
inhibitor and antiproliferative agent.
23
Scheme 1. Synthesis of 5-Bromo-1H-pyrazolo[3,4-b]-
pyridine-3-carboxylic acid (3)
a
aReagents and conditions: (i) KMnO4, NaOH, 3 h, 100 C, H2SO4;
35
(ii) methanol, H2SO4,r e ﬂux, 6 8 h, NaHCO3, 42% (i + ii);
35 (iii) Br2,
AcOH, AcONa, 115 C, overnight, chromatographic puriﬁcation,
43%;
23 (iv) NaOH, MeOH, reﬂux, 4 h, HCl, 100%;
23 (v) Br2, AcOH,
AcONa, 115 C, 2.5 3 h; and (vi) KMnO4, NaOH, 3 h, 100 C, HCl,
24 35% (v + vi).
Scheme 2. Synthesis of 1-Methoxymethyl-2,3-diamino-
benzene (5)
a
aReagents and conditions: (i) NaH, MeI, dry THF, 0 C, 30 min, room
temperature, overnight, chromatographic puriﬁcation, 34% yield;
23 (ii)
NaH, MeI, dry THF, 0 C, 15 min, room temperature, 3 h, chromato-
graphic puriﬁcation, 65 75% yield; (iii) 10% Pd/C, ethanol, H2, room
temperature, 18 24 h, 100% yield.11722 dx.doi.org/10.1021/ic201704u |Inorg. Chem. 2011, 50, 11715–11728
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For the synthesis of L1 L3, we used N,N0-carbonyldiimida-
zole (CDI) as an amide-coupling reagent, because it is relatively
inexpensiveandthesideproducts,carbondioxideandimidazole,
could be easily removed from the reaction mixture.
CDI-mediated amidation of acids 1 and 3 was performed as
shown in Scheme 3 (steps i and ii). In the ﬁrst step, the acyl-
imidazolides 6 and 7 were obtained in dry DMF at room
temperature and isolated as white solids. The yields based on
3-methyl-1H-pyrazolo[3,4-b]pyridine are: 25 29% (6) and
13 16% (7). In the second step, monoacylation of phenylene-
diamines(1,2-diaminobenzeneand1-methoxymethyl-2,3-diami-
nobenzene (5)) using acyl-imidazolides was performed in DMF
at 80 85 C.
Amides 8 10 were used without further puriﬁcation in ring
closure reactions in a glacial acetic acid at 120 125 Ca n d
aﬀordedthedesired3-(1H-benzimidazol-2-yl)-1H-pyrazolo[3,4-b]-
pyridines:L1(55 60%),L2(58 61%),andL3(44 51%),based
on6and7(seeScheme3,stepiii).ThereportedsynthesisofL3isa
one-potapproachforamideformationusingHATUwith57%yield,
followed by cyclization under acidic conditions (acetic acid) with
87% yield.
Thus, the ligands L1, L2, and L3 have been prepared in 7, 8,
and 11 steps, correspondingly.
Finally, the ligands L1 L3 were reacted with [M
IICl2(η
6-p-
cymene)]2(whereM=Ru,Os)ina2:1molarratioindryethanol
at room temperature to give [MCl(η
6-arene)(L)]Cl complexes
(11a, 11b, 12a, 12b, 13a, 13b) in quantitative yields. Crystal-
lization of [Ru
IICl(η
6-p-cymene)(L3)]Cl (13a)i nE t O Ho r
EtOH/Et2O resulted in XRD-quality crystals of [Ru
IICl(η
6-p-
cymene)(L3 H)] (13c),whilethecrystallizationof13ainmethanol
aﬀorded crystals of composition [Ru
IICl(η
6-p-cymene)(L3)]Cl3
[Ru
IICl(η
6-p-cymene)(L3 H)]3CH3OH (13d3CH3OH). The
osmium(II) analogue 13e30.75CH3OH30.25H2Ow a so b t a i n e d
via the crystallization of 13b in methanol.
NMREvidenceofLigandCoordination.Thefullassignment
ofproton,carbon,andnitrogenresonancesforL1 L3,11a,11b,
12a, 12b, 13a, and 13b is quoted in Tables S1 S3 in the
Supporting Information.
3-(1H-Benzimidazol-2-yl)-1H-pyrazolo[3,4-b]pyridines with an
unsubstituted benzimidazole moiety (L1, L2) display one set of
signals. L1 is characterized by three doublets of doublets for H4a,
H5a,H 6a (8.85, 7.39, 8.66 ppm, correspondingly) of pyrazolopyr-
idine moiety, two doublets for H4b,H 7b (7.54 and 7.75 ppm), the
overlappedH5b,H 6bprotonsignalsinonemultiplet(7.24ppm)for
abenzimidazolemoietyandtwosingletresonancesforH1aandH1b
(for atom numbering, see Chart 1). The substitution of H5a by
bromine (L2) results in reduced multiplicity for the H4a and H6a
signals (two doublets at 8.99 and 8.75 ppm), whereas the benzi-
midazole moiety spectrum remains almost unchanged. Two sing-
letswere attributed to NHprotonsand related to pyrazolopyridine
(H1a, at 14.19 (L1), 14.43 (L2) ppm) and benzimidazole (H1b,a t
13.11 (L1), 13.19 (L2)p p m )m o i e t i e s .
NMR spectra for 11a, 11b, 12a, and 12b, where L1 and L2
coordinate as bidentate ligands via N2a and N3b with the
formation of a stable ﬁve-membered chelate cycle, show one
set of signals. There was no evidence for monodentate or
tridentatecoordinationofligandswiththeformationofdinuclear
or polynuclear complexes.
Coordination of L1 and L2 to ruthenium(II) made it possible
to assign the two doublets to proton resonances of H4b and H7b
of the benzimidazole moiety. In the
1H,
1H ROESY plots, one of
them has cross-peaks with a CH cymene ring and the nearest to
them is H4b (e.g., at 8.11 (11a), 8.06 (12a) ppm). A singlet at
14.91 (11a), 14.34 (12a) ppm was assigned to NH proton and
showed no couplings with other atoms. The nitrogen resonance
shift at 128.7 (11a), 127.3 (12a) ppm is closer to the benzimi-
dazole NH chemical shift in metal-free ligands (121.3 (L1, L2)
ppm) and, therefore, was assigned as N1b (see Table S3 in the
SupportingInformation).TheH1bresonanceshowsasigniﬁcant
shift by 1.8 and 1.15 ppm for 11a and 12a, respectively, upon
ligand coordination (L1 and L2) to the metal(II)-arene moiety.
Scheme 3. Synthesis of 3-(1H-Benzimidazol-2-yl)-1H-pyrazolo[3,4-b]pyridines L1 L3
a
aReagentsandconditions:(i)CDI,dryDMF,roomtemperature,20 24h;(ii)1,2-diaminobenzeneor5,dryDMF,80 85C;5 20h;and(iii)glacial
AcOH, 120 125 C, 2.5 4.5 h, chromatographic puriﬁcation.
Figure 1. Part of the
1H,
1H ROESY plot of L3.11723 dx.doi.org/10.1021/ic201704u |Inorg. Chem. 2011, 50, 11715–11728
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The nearest to the metal binding site pyrazolopyridine proton
H1a was not detected for 11a, 11b, 12a, and 12b, and the proton
resonance of H1b was also not seen for 11b or 12b.
L3 displays two sets of signals originated from 7b-L3 and 4b0-
L3 tautomers (see Chart 1). The signals of pyrazolopyridine
moieties are partially overlapped (e.g., H1a (H1a0) at 14.47 and
14.43 ppm, H4a (H4a0) at 8.99 and 8.98 ppm, H6a (H6a0) at 8.75
ppm), whereas the signals of the benzimidazole moieties are
better resolved (see Table S1 in the Supporting Information).
Accordingtothe
1H,
1HROESYplot,oneoftheCH2groupsat
4.80 ppm couples with the NH proton at 13.25 ppm, indicating
their attribution to the 7b-L3 tautomer, whereas another NH
protonat13.22ppmgivesacross-peakwithH7b0 at7.47ppmand
belongs to 4b0-L3 tautomer (Figure 1).
Tautomers 7b-L3 and 4b0-L3 are present in solution in 1:1.3
molar ratio and give, for the substituted benzimidazole moiety,
twosinglets(H1b0 at13.22ppm,H1bat13.25ppm),twodoublets
of doublets (H7b0 at 7.47 ppm, H4b at 7.72 ppm), one multiplet
(H5b,H 6b,H 5b0,H 6b0 at7.28 7.21ppm),twoCH2(4.80(H10b),
4.96 (H10b0) ppm) and two CH3 singlets at 3.37 (H11b) and 3.44
(H11b0) ppm. The absence of cross-peaks between H7b0 and H4b
in the
1H,
1H COSY plot supports their relation to the two
diﬀerent molecules.
The binding site in 4b0-L3 tautomer is sterically shielded by a
methoxymethyl group. Consistent with this NMR spectra dis-
play, only one set of signals is shown for 13a and 13b with the
coordination of the 7b-L3 tautomer to ruthenium(II) and
osmium(II) via N2a and N3b (see Scheme 4).
The preference for coordination of the 7b-L3 tautomer is also
conﬁrmed by
1H,
1H ROESY plots: H4b (7.99 (13a), 7.91 (13b)
ppm)has couplings withCH protonsof cymenering. The cross-
peak between H10b at 4.88 ppm (13a) and NH at 13.88 ppm -
(13a) enabled the assignment of this singlet to a benzimidazole
moiety (H1b). In addition, the chemical shifts for the C atoms of
the benzimidazole moiety (C4b,C 7b,C 5b,C 6b) of the coordi-
nated ligand and metal-free 7b-L3 tautomer are very similar (see
Table S2 in the Supporting Information). The nitrogen reso-
nance at 122.9 ppm (13a) compares well to the benzimidazole
NHchemicalshiftinmetal-freeL3at121.4ppm.Asfor11a,11b,
12a, and 12b, the nearest to the coordination place pyrazolopyr-
idine proton H1a resonance was not detected.
According to the
1H,
1H ROESY plots of 11a, 12a, 13a, and
13b only CH cymene ring protons have couplings with the
nearestH4bbenzeneringproton,suggestingthattheisopropylor
methyl groups are further away from the H4b proton.
CrystalStructures.TheresultsoftheXRDstudiesof[Os
IICl(η
6-
p-cymene)(L1)]Cl34H2O( 11b34H2O), [Os
IICl(η
6-p-cymene)-
(L2)]Cl (12b), [Os
IICl(η
6-p-cymene)(L2)]Cl32CH3OH32H2O
(12b32CH3OH32H2O), [Ru
IICl(η
6-p-cymene)(L3 H)] (13c),
[Ru
IICl(η
6-p-cymene)(L3)]Cl3[Ru
IICl(η
6-p-cymene)(L3 H)]3
CH3OH (13d3CH3OH) and [Os
IICl(η
6-p-cymene)(L3)]Cl3
[Os
IICl(η
6-p-cymene)(L3 H)] 30.75CH3OH30.25H2O( 13e30.75-
CH3OH30.25H2O) are shown in Figures 2, Figure S2 in the
SupportingInformation,andFigures3 6,respectively.Allcomplexes
have a typical “three-legged piano-stool” geometry of ruthenium(II)
andosmium(II) arenecomplexes,withanη
6π-boundp-cymenering
formingtheseatandthreeotherdonoratoms(twonitrogensN1and
Scheme 4. Coordination of L3 (7b-L3 (left) and 4b0-L3
(right) Tautomers)
Figure 2. Fragment of the crystal structure of 11b34H2O showing
nitrogen atoms N3 and N4, which act as proton donors in intermole-
cular hydrogen bonding interactions N3 H333Cl2 [N3333Cl2
3.067(7) Å, N3 H333Cl2 177.3] and N4 H333O3 [N4333O3
2.671(9) Å, N4 H333O3 170.9]; thermal ellipsoids have been drawn
at 50% probability level. Selected bond lengths and angles: Os Cl1,
2.421(2)Å;Os N1,2.072(7)Å;Os N5,2.096(7)Å;Os C(arene)av,
2.198(32) Å; C1 N2, 1.349(11) Å; N2 N1, 1.366(10) Å; N1 C6,
1.357(11) Å; C6 C7, 1.428(12) Å; C7 N5, 1.345(11) Å; N5 C13,
1.391(11) Å; N1 Os N5, 75.6(3);N 1  Os Cl1, 85.5(2);
N5 Os Cl1, 83.4(2).
Figure 3. ORTEP plot of the structure of the cation [Os
IICl(η
6-p-
cymene)(L2)]
+in12b32CH3OH32H2O.Thermalellipsoidshavebeen
drawn at the 50% probability level. Selected bond lengths and angles:
Os Cl1, 2.4043(1) Å; Os N1, 2.083(3) Å; Os N5, 2.097(3) Å;
Os C(arene)av, 2.197(26) Å; C1 N2, 1.361(5) Å; N2 N1,
1.344(4) Å; N1 C6, 1.336(5) Å; C6 C7, 1.447(6) Å; C7 N5,
1.335(5) Å; N5 C13, 1.380(5) Å; N1 Os N5, 74.73(13),
N1 Os Cl1, 84.29(10); and N5 Os Cl1, 83.25(10).11724 dx.doi.org/10.1021/ic201704u |Inorg. Chem. 2011, 50, 11715–11728
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N5ofthecorresponding3-(1H-benzimidazol-2-yl)-1H-pyrazolo[3,4-
b]pyridine and one chlorido ligand) as the legs of the stool. Selected
bond distances and angles are quoted in the figure captions. All
complexes crystallize as racemates, because of the presence of the
stereogenic metal center.
The bidentate3-(1H-benzimidazol-2-yl)-1H-pyrazolo[3,4-b]-
pyridines, which can have diﬀerent substituents in positions 5a
and 7b, reveal diﬀerent acid base properties. It can act as a
neutralorganicligand,withnitrogenatomsN2andN4asproton
donors involved in intermolecular hydrogen bonding interac-
tions N4 H333O1
i( x +1 , y +1 , z + 2) [N4333O1
i,
2.730(4)Å;N4 H333O1
i,176.1]andN2 H333O3
ii( x+2,
 y+1, z+1[N2333O3
ii,2.697(4)Å;N4 H333O1
i,172.3]
withonemethanolandonewatermolecule,respectively,asisthe
case for 12b32CH3OH32H2O (Figure 3) or N2 H333Cl2-
(Cl2X) and N4 H333Cl1
i( x,  y,  z + 2) [N4333Cl1
i,
3.213(9) Å; N4 H333O1
i, 162.91]i n12b (see Figure S2 in
theSupportingInformation),correspondingly.Theligandcanbe
protonated at N3 (N3 H333Cl2) and deprotonated at N2
[N2333H O4
i ( x +1 , y +1 , z + 1) with N2333O4
i
2.923(9) Å, N2333H O4
i 138.7] (overall charge zero) with
atom N4 as a proton donor to one of the four co-crystallized
water molecules N4 H333O3, as occurs in 11b34H2O (see
Figure 2).
In 13c, the ligand was found to be deprotonated at N2, acting
as a proton acceptor in the intermolecular hydrogen bonding
interaction N2333H N4
i (i denotes symmetry transformations
x,  y + 1.5, z + 0.5) used to generate equivalent atoms)
[N2333N4
i, 2.896(7) Å; N2333H N4
i, 155.6] (see Figure 4).
Complexes 13d3CH3OH and 13e30.75CH3OH30.25H2O
crystallized both in the centrosymmetric triclinic space group
P1. The asymmetric unit in both consists of a neutral complex
[M
IICl(η
6-p-cymene)(L3 H)] andacomplex cation[M
IICl(η
6-
p-cymene)(L3)]
+ (M = Ru or Os), a chloride counteranion and
co-crystallized solvent (methanol or methanol/water). Deproto-
nation of the organic ligand in [M
IICl(η
6-p-cymene)(L3 H)] is
corroborated by the presence of hydrogen bonding of the type
N2a333H N2b
i( x+1, y+1, z+1)inthecrystalstructure
of the ruthenium complex 13d3CH3OH (Figure 5) and a similar
interactionN2b333H N2a
i(x,y +1,z)[ N 2 b333N2a
i, 2.810(9)
Å;N2b333H N2a
i,170.1]inthecrystaloftheosmiumanalogue
13e30.75CH3OH30.25H2O. In Figure 6 the structure of
[Os
IICl(η
6-p-cymene)(L3 H)] is shown. In both structures,
Figure 6. ORTEP plot of [Os
IICl(η
6-p-cymene)(L3 H)] in [Os
IICl-
(η
6-p-cymene)(L3)]Cl3[Os
IICl(η
6-p-cymene)(L3 H)]30.75CH3OH3
0.25H2O( 13e30.75CH3OH30.25H2O). Thermal ellipsoids have been
drawn at the 40% probability level. Selected bond lengths and angles:
Os1a Cl1a, 2.402(2) Å; Os1a N1a, 2.068(7) Å; Os1a N5a, 2.086(7) Å;
Os1a C(arene)av, 2.192(25) Å; C1a N2a, 1.349(10) Å; N2a N1a
1.369(9) Å; N1a C6a, 1.361(10) Å; C6a C7a, 1.431(11) Å; C7a N5a,
1.339(10) Å; N5a C13a, 1.398(11) Å; N1a Os1a N5a, 75.1(3);
N1a Os1a Cl1a, 83.56(18);a n dN 5 a  Os1a Cl1a, 84.2(2).
Figure4. ORTEPplotofthecomplex[Ru
IICl(η
6-p-cymene)(L3 H)]
(13c). Thermal ellipsoids have been drawn at 30% probability level.
Selected bond lengths and angles: Ru Cl, 2.399(2) Å; Ru N1,
2.067(6) Å; Ru N5, 2.089(5) Å; Ru C(arene)av, 2.186(31) Å; C1 
N2, 1.366(8) Å; N2 N1, 1.353(7) Å; N1 C6, 1.362(7) Å; C6 C7,
1.426(9) Å; C7 N5, 1.335(8) Å; N5 C13, 1.398(8) Å; N1 Ru N5,
75.9(2);N 1  Ru Cl, 87.35(17); and N5 Ru Cl, 85.73(17).
Figure 5. Fragment of the crystal structure of [Ru
IICl(η
6-p-cymene)-
(L3)]Cl3[Ru
IICl(η
6-p-cymene)(L3 H)]3CH3OH (13d3CH3OH)
showing the intermolecular hydrogen bonding N2a H333N2b
[N2a333N2b
i ( x +1 , y +1 , z + 1), 2.814(7) Å; N2a H333N2b
i,
163.3]. Selected bond lengths and angles: Ru1a Cl1a, 2.3952(17) Å;
Ru1a N1a, 2.078(5) Å; Ru1a N5a, 2.099(5) Å; Ru1a C(arene)av,
2.194(33) Å; C1a N2a, 1.358(8) Å; N2a N1a, 1.354(7) Å; N1a C6a,
1.350(8) Å; C6a C7a, 1.441(9) Å; C7a N5a, 1.335(8) Å; N5a C13a,
1.381(8) Å; N1a Ru1a N5a, 75.6(2);N 1 a  Ru1a Cl1a, 84.45(15);
and N5a Ru1a Cl1a, 85.05(15).11725 dx.doi.org/10.1021/ic201704u |Inorg. Chem. 2011, 50, 11715–11728
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the atoms N4a and N4b act as proton donors in strong hydrogen
bonding interactions to the chloride counteranion, namely, N4a333
H Cl2
ii ( x +1 , y +2 , z +1 )[ N 4 333Cl2
ii, 3.275(6) Å;
N4a333H Cl2
ii, 176.9], N4b333H Cl2 [N4b333Cl2, 3.211(5)
Å; N4b333H Cl2, 176.0]( 13d3CH3OH) and N4a333H Cl2
ii
( x +1 , y +1 , z +1 )[ N 4 a 333Cl2
ii, 3.273(8) Å; N4a333
H Cl2
ii, 177.0], N4b333H Cl2
ii [N4b333Cl2, 3.204(7) Å;
N4b333H Cl2, 177.0]( 13e30.75CH3OH30.25H2O).
Antiproliferative Activity. Ligands L1 L3, as well as the
corresponding ruthenium(II) (11a 13a) and osmium(II)
(11b 13b) arene complexes, were studied with regard to their
capacityofinhibitingcellgrowthinvitrointhehumancancercell
lines CH1 (ovarian carcinoma), SW480 (colon carcinoma), and
A549(non-smallcelllung cancer), yielding the IC50values listed
in Table 2. All compounds show the strongest effect in the
generally chemosensitive CH1 cells, whereas the more chemore-
sistant A549 cells are also less affected by the compounds
investigated here. The antiproliferative activity of the metal-free
ligands decreases in the rank order L3 > L2 > L1, indicating that
bromination(L2,L3)and,evenmoreso,thedoublesubstitution
(bromination and an additional replacement of H by a methox-
ymethyl group (L3)) are advantageous, with regard to activity.
These structure activity relationships are also reflected in the
rank orders of the corresponding ruthenium and osmium com-
plexesfortherutheniumcomplexes,13a>12a>11a,andforthe
osmium complexes, 13b > 12b > 11b.
However, the IC50 values are shifted to higher concentrations
(see Figure 7). The diﬀerences between the ruthenium and
osmiumanaloguesaremostlysmall(IC50valuesdiﬀeronlyupto
a factor of 2.4), with the osmium complexes being at least as
active as their ruthenium counterparts.
CellCycleEffects.Since3-(1H-benzimidazol-2-yl)-1H-pyrazolo-
[3,4-b]pyridineshavebeenreportedtobepotentCdkinhibitors,we
expectedtheinvestigated ligands andcomplexestoinduce cellcycle
perturbations. To confirm this assumption in a sensitive cell line,
exponentially growing CH1 cells were treated with the compounds
for24h,stainedwithpropidiumiodide,andanalyzedfortheirDNA
content by fluorescence-activated cell sorting (FACS). Surprisingly,
the metal-free ligands L1 L3 turned out to exert only modest
effects on cell cycle distribution, with a slight increase of the G2/M
fraction from 32% in the untreated control to 53% by 20 μM L2 as
the strongest effect observed in this setting (higher concentrations
of this compound led to disintegration of cells already after 24 h).
However,thelesscytotoxicrutheniumcomplexes12aand13a,both
bearing substituted ligands (L2 and L3 correspondingly), cause a
more pronounced G2/M phase arrest, as reflected by an increaseof
this cell fraction to 65% at 80 μM and 59% at 40 μM, respectively,
and a concomitantdecrease of theG0/G1fraction to 21%and 24%
(compared to 42% in controls), whereas ruthenium complex 11a
bearing an unsubstituted ligand L1 is devoid of activity on the cell
cycle. On the other hand, the osmium complexes do not generally
show stronger effects on the cell cycle than the metal-free ligands,
perhapswiththeexceptionof13b,whichinducesanincreaseofthe
G2/M fraction up to 53% at 80 μM, accompanied by a decline of
the G0/G1 fraction to 31% (see Figure 8).
Cdk-Inhibitory Activity. Although the lack of generally
pronounced cell cycle effects does not argue for a strong role
of Cdk inhibition in the mechanism of action of the investigated
compounds,inhibitorypotencieswerestudiedincell-freeexperi-
mentswithtworecombinantCdk/cyclincomplexes,bymeansof
the histone H1 kinase assay. Results reveal that all compounds
are capable of inhibiting kinase activities in a concentration-
dependent manner, being more effective on Cdk2/cyclin E than
Table 2. Antiproliferative Activity of Metal-Free Ligands
(L1 L3),andTheirRuthenium(II) (11a 13a)andOsmium(II)
(11b 13b) Arene Complexes, in Three Human Cancer Cell
Lines (CH1, SW480, and A549)
a
IC50 [μM]
b
compound metal CH1 SW480 A549
L1 11 ( 32 3 ( 62 9 ( 7
11a Ru 96 ( 18 >320 525 ( 102
11b Os 64 ( 19 223 ( 29 >640
L2 1.5 ( 0.6 5.1 ( 1.0 6.7 ( 0.3
12a Ru 21 ( 37 0 ( 8 268 ( 35
12b Os 22 ( 32 9 ( 2 123 ( 21
L3 0.63 ( 0.09 0.74 ( 0.26 5.2 ( 0.5
13a Ru 11 ( 11 1 ( 26 8 ( 12
13b Os 7.9 ( 2.2 12 ( 28 9 ( 11
aCH1 denotes ovarian cancer, human; SW480 denotes colon carcino-
ma, human; and A549 denotes non-small-cell lung carcinoma, human.
b50% inhibitory concentrations (meanvalue (standard deviation from
at least three independent experiments) obtained by the MTT assay
(96-h exposure).
Figure 7. Concentration eﬀect curves ofeach ligand,compared to the
corresponding ruthenium and osmium complexes, in CH1 ovarian
cancer cells (MTT assay, 96 h exposure): (A) L1, 11a, 11b; (B) L2,
12a,12b;and(C)L3,13a,13b.Boththepresenceofsubstituentsinthe
ligands and complexation result in a marked shift of antiproliferative
activity.11726 dx.doi.org/10.1021/ic201704u |Inorg. Chem. 2011, 50, 11715–11728
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on Cdk1/cyclinB (see Figure 9). In contrast to theobserved cell
cycle effects, but in accordance with antiproliferative activities,
Cdk-inhibitory potency of the metal-free ligands is consistently
higher than that of the metal complexes. In particular, only
L1 L3 effectively inhibit Cdk2/cyclin E in low concentrations
(1 μMo r1 0μM), whereas all complexes require higher
concentrations to exert >50% inhibitory effects. As in the
MTT assay, differences between the effects of corresponding
ruthenium and osmium complexes are minor, compared to the
differences from those of the metal-free ligands.
’CONCLUSION
The known multistep synthesis of 3-(1H-benzimidazol-2-yl)-
1H-pyrazolo[3,4-b]pyridines, which we have modiﬁed, essen-
tially aﬀorded three organic compounds (L1 L3) that possess
Cdk-inhibiting properties. These were used as bidentate ligands,
and six novel organometallic complexes of the general formula
[M
IICl(η
6-p-cymene)(L)]Cl, where M = Ru (11a, 12a, 13a)o r
Os (11b, 12b, 13b) and L = L1 L3, have been synthesized and
comprehensively characterized using spectroscopic and X-ray
diﬀractionmethods.ComplexationofL1 L3withrutheniumor
osmium yielded compounds with increased solubility in the
biological medium, yet lowered antiproliferative activity in hu-
man cancer cell lines. Modulation of biological activities by
substitution at the ligands can be accomplished in the metal-free
moleculesandtheirmetalcomplexesinasimilarway.Theknown
Cdk-inhibitory activity of the ligands could be conﬁrmed in cell-
Figure 8. Concentration-dependent eﬀects of metal-free ligands (top), and the corresponding ruthenium (middle) and osmium complexes (bottom),
on the cell cycle distribution of CH1 cells (( 2) G0/G1, (O) S, and (9) G2/M phase). Note the diﬀerent concentration scales.
Figure 9. Concentration-dependent eﬀects of metal-free ligands (L1 L3)
as well as corresponding ruthenium (11a 13a) and osmium complexes
(11b 13b), on kinase activities of recombinant Cdk1/cyclin B (top) and
Cdk2/cyclin E (bottom).11727 dx.doi.org/10.1021/ic201704u |Inorg. Chem. 2011, 50, 11715–11728
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free experiments, in particular in Cdk2/cyclin E, and their
stronger eﬀects on Cdk activity parallel their higher capacity of
inhibiting cancer cell growth in vitro, compared to their metal
complexes. Nevertheless, the lack of pronounced eﬀects on the
cell cycle of chemosensitive ovarian cancer cells argues against a
major role for inhibition of cell growth, at least in this setting.
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